Scarica l'app Stockscreener
4.07
1.75%
0.07
Dopo l'orario di chiusura:
4.07
Precedente Chiudi:
$4.00
Aprire:
$4.03
Volume 24 ore:
5,001
Relative Volume:
0.06
Capitalizzazione di mercato:
$3.00M
Reddito:
$4.79M
Utile/perdita netta:
$-13.42M
Rapporto P/E:
-1.5301
EPS:
-2.66
Flusso di cassa netto:
$-10.30M
1 W Prestazione:
-4.91%
1M Prestazione:
-3.78%
6M Prestazione:
-73.75%
1 anno Prestazione:
-84.19%
Intervallo 1D:
$4.0001
$4.15
Intervallo di 1 settimana:
$3.95
$4.35
Portata 52W:
$3.3358
$29.43
Qualigen Therapeutics Inc Stock (QLGN) Company Profile
Nome
Qualigen Therapeutics Inc
Settore
Industria
Telefono
(760) 918-9165
Indirizzo
2042 CORTE DEL NOGAL, CALIFORNIA
Confronta QLGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QLGN
Qualigen Therapeutics Inc
|
4.07 | 3.00M | 4.79M | -13.42M | -10.30M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Qualigen Therapeutics Inc Borsa (QLGN) Ultime notizie
Microbiomes Market to Grow by USD 1.13 Billion (2024-2028), Driven by Rising Disease Prevalence; AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Qualigen Therapeutics (NASDAQ:QLGN) Stock Price Down 5.2% – Time to Sell? - Defense World
Qualigen Therapeutics (NASDAQ:QLGN) Shares Down 5.2% – Here’s Why - Defense World
Qualigen Therapeutics (NASDAQ:QLGN) Trading Down 7.8% – Time to Sell? - Defense World
SEC Form S-1 filed by Qualigen Therapeutics Inc. - Quantisnow
Qualigen Therapeutics regains compliance with Nasdaq's listing requirements - MSN
Qualigen Therapeutics regains Nasdaq compliance By Investing.com - Investing.com UK
Qualigen Therapeutics Announces Regained Compliance with - GlobeNewswire
Qualigen Therapeutics Announces Regained Compliance with Nasdaq's Minimum Bid Price Requirement and the Equity Requirement - Yahoo Finance
Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN) - The Manila Times
Univest Securities, LLC Announces Successful Closing of - GlobeNewswire
Qualigen Therapeutics, Inc. announced that it expects to receive $5.1 million in funding - Marketscreener.com
Qualigen Therapeutics secures $4.5 million in funding By Investing.com - Investing.com South Africa
Qualigen Therapeutics secures $4.5 million in funding - Investing.com India
Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares - The Manila Times
Qualigen Therapeutics (NASDAQ:QLGN) versus Ionis Pharmaceuticals (NASDAQ:IONS) Head-To-Head Review - Defense World
Qualigen Therapeutics Inc (QLGN) Quarterly 10-Q Report - Quartzy
Qualigen Therapeutics appoints new board member - Investing.com
Qualigen Therapeutics appoints new board member By Investing.com - Investing.com Canada
QLGN Stock Touches 52-Week Low at $3.71 Amid Market Challenges - Investing.com Canada
Qualigen Therapeutics announces 1-for-50 reverse stock split - Investing.com India
Qualigen Therapeutics announces 1-for-50 reverse stock split By Investing.com - Investing.com UK
Qualigen Therapeutics (STU:7R90) Enterprise Value : €4.58 Mil (As of Nov. 07, 2024) - GuruFocus.com
Qualigen Therapeutics (STU:7R90) Operating Cash Flow per Sh - GuruFocus.com
Qualigen Therapeutics (STU:7R90) Financial Strength : 4 (As of Jun. 2024) - GuruFocus.com
Qualigen Therapeutics (STU:7R90) Shares Outstanding (EOP) : 0.19 Mil (As of Jun. 2024) - GuruFocus.com
Qualigen Therapeutics (STU:7R90) Long-Term Debt & Capital L - GuruFocus.com
Qualigen Therapeutics (STU:7R90) EV-to-Revenue : (As of Nov. 07, 2024) - GuruFocus.com
Qualigen Therapeutics (STU:7R90) Cash Flow from Financing : €1.51 Mil (TTM As of Jun. 2024) - GuruFocus.com
Qualigen Therapeutics, Inc. Announces Chief Financial Officer Changes - Marketscreener.com
Qualigen Therapeutics, Inc. Announces Appointment of Amy Broidrick as Executive Vice President and Chief Strategy Officer - Marketscreener.com
QLGN stock touches 52-week high at $5.05 amid market fluctuations - Investing.com
Qualigen Therapeutics Stock to Reverse Split on Tuesday, November 5th (NASDAQ:QLGN) - Defense World
Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024 - GlobeNewswire
Would I Buy Qualigen Therapeutics Inc (NASDAQ: QLGN) Stock At Any Time In The Future? - Stocks Register
Qualigen Therapeutics announces results of annual stockholder meeting By Investing.com - Investing.com Australia
Qualigen Therapeutics announces results of annual stockholder meeting - Investing.com India
Qualigen Therapeutics (STU:7R9) Enterprise Value : €4.47 Mil (As of Oct. 26, 2024) - GuruFocus.com
Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG - openPR
QLGN stock touches 52-week low at $0.11 amid market challenges - Investing.com India
Qualigen Therapeutics faces Nasdaq delisting notice By Investing.com - Investing.com Canada
Qualigen Therapeutics faces Nasdaq delisting notice - Investing.com India
Qualigen Therapeutics (NASDAQ:QLGN) Shares Up 4.4% – Here’s Why - Defense World
Qualigen Therapeutics appoints new director and audit chair By Investing.com - Investing.com South Africa
Qualigen Therapeutics appoints new director and audit chair - Investing.com India
Qualigen Therapeutics Inc Azioni (QLGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.65%
4.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):